April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Effects of Commercially Available Preservative-free Fda Approved Triamcinolone (Triesence®) on Retinal Cells in Culture
Author Affiliations & Notes
  • Leandro C. Zacharias
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
    University of California, Irvine, California
  • Maria F. Estrago-Franco
    University of California, Irvine, California
    Ophthalmology, Clinica Dres Estrago, Corrientes, Argentina
  • Walter Takahashi
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Claudio A. Ramirez
    Ophthalmology,
    University of California, Irvine, California
  • Maria C. Kenney
    Ophthalmology,
    University of California, Irvine, California
  • Baruch D. Kuppermann
    Gavin Herbert Eye Inst Dept Ophthalmolog, University of California Irvine, Irvine, California
  • Footnotes
    Commercial Relationships  Leandro C. Zacharias, None; Maria F. Estrago-Franco, None; Walter Takahashi, None; Claudio A. Ramirez, None; Maria C. Kenney, None; Baruch D. Kuppermann, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5667. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Leandro C. Zacharias, Maria F. Estrago-Franco, Walter Takahashi, Claudio A. Ramirez, Maria C. Kenney, Baruch D. Kuppermann; The Effects of Commercially Available Preservative-free Fda Approved Triamcinolone (Triesence®) on Retinal Cells in Culture. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5667.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effects of commercially available preservative free triamcinolone acetonide (Triesence®) on retinal cells in culture.

Methods: : Human RPE (ARPE-19) and rat retinal neurosensory (R28) cell cultures were treated with 100, 200, 500 or 1000 µg/ml of crystalline (c) or solubilized (s) TRI for 24 hours. Triesence was solubilized by first centrifuging the drug and then discarding the supernatant containing the vehicle and preservative. The drug pellet was resuspended in an equivalent amount of Dimethyl sulfoxide (DMSO) to achieve the same concentration as the commercial preparation. Cell Toxicity was evaluated by trypan blue dye-exclusion assay (cTRI and sTRI), JC1 assay to measure mitochondrial damage (sTRI only), and caspase-3/7 activity to measure apoptosis (sTRI).

Results: : Compared to untreated controls, cTRI caused a decrease in cell viability in all concentrations and cell lines tested (13.03±6.51, 28.87±9.3, 54.93±5.61 and 82.53±0.65 for ARPE 1000, 500, 200 and 100 µg/ml vs. 96.98±0.16 for untreated controls, p<0.001, except for 100 µg/ml vs. untreated, p<0.05; 22.73±2.44, 34.63±1.91, 58.70±1.39 and 75.33±2.47 for R28 1000, 500, 200 and 100 vs. 86.08±3.54 for untreated controls, p<0.001). sTRI did not reduce viability or JC1 mitochondrial membrane potential of either cell line at any concentration tested. However, caspase 3/7 upregulation was detected in both cell lines. For the ARPE-19 it was observed when sTRI 200, 500 and1000 µg/ml was compared to untreated cells or DMSO controls (p<0.01). For R28 cells, caspase 3/7 upregulation was observed when compared sTRi 200, 500 and 1000 µg/ml to DMSO controls (P<0.05 for 200 µg/ml, p<0.01 for 500 and 1000 µg/ml) but only 1000 µg/ml was statistically significant when compared to untreated cells (P<0.01).

Conclusions: : Crystalline Triesence® causes significant decrease in cell viability in retinal cells in culture. Cell death was not observed after the drug was solubilized, though caspase 3/7 upregulation was noted. This suggests that Triesence® can damage retinal cells in vitro via caspase-dependent apoptosis, similar to Kenalog® and compounding pharmacy produced preservative-free triamcinolone.

Keywords: retinal culture • retinal pigment epithelium • ocular irritancy/toxicity testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×